Metraipolis › archive › dc_db91ccbba1c1

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial — Europe PMC PMID:42231943

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42231943
DOI
10.1093/ofid/ofag266
License (as archived)
solo-consultazione
Archived
2026-11-02T17:10:43.814Z
SHA-256 of the archived text
2523eb8ba31dc16b771a79eb8d6624fa2a74bc124618ec9f86e797094fdc975a
Stable URL of this page
https://metraipolis.com/documento/dc_db91ccbba1c1

How to cite

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial — Europe PMC PMID:42231943 — Europe PMC (en), https://europepmc.org/article/MED/42231943 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db91ccbba1c1 (Metraipolis archive dc_db91ccbba1c1, sha256 2523eb8ba31dc16b771a79eb8d6624fa2a74bc124618ec9f86e797094fdc975a)
BibTeX
@misc{dcdb91ccbba1c1,
  title = {Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial — Europe PMC PMID:42231943},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42231943},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db91ccbba1c1; sha256 2523eb8ba31dc16b771a79eb8d6624fa2a74bc124618ec9f86e797094fdc975a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42231943. Agents can read the archived copy with the MCP tool read_document.